In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
1824 News Items found
Lab coat with the MSK logo hangs in a lab
MSK Research Highlights, November 20, 2025

New MSK research finds a potential therapeutic opportunity in regulatory T cells’ resilience to the loss of Foxp3; shows how cancer develops resistance to antibody-drug conjugates; develops a new system to help make gene editing safer and more reliable; and shows provider billing margin doesn’t drive cancer treatment selection.
A researcher points to cells on a screen
Memorial Sloan Kettering Cancer Center Applauds Highly Cited Researchers 2025

In 2025, MSK was again ranked among the top organizations with the greatest number of highly cited scientific researchers worldwide, according to the annual list of Highly Cited Researchers, published by the Institute for Scientific Information at Clarivate.
Microscope in foreground. GSK Graduate Students in the background.
Training Tomorrow’s Leaders: Graduate Education at GSK

Since its founding 19 years ago, the Gerstner Sloan Kettering Graduate School of Biomedical Sciences has attracted bright minds drawn to its connection to MSK. Learn more about how we're training tomorrow's leaders.
Clinical Social Worker Barbara Mitchell is seen smiling.
Talking About a Lung Cancer Diagnosis With Family, Friends, and Others

Learn how to talk about your lung cancer diagnosis with family, friends and others — including questions about smoking.
hematopoietic stem and progenitor cells
MSK Researchers Make Strides Against VEXAS Syndrome

VEXAS syndrome is a confounding adult-onset inflammatory disease first described in 2020, which affects 1 in 4,000 men over 50. Now, MSK researchers are shedding new light on its mechanisms and laying the groundwork for potential targeted treatments.
A researcher working in an MSK lab
MSK Research Highlights, October 31, 2025

New MSK research uncovers unique genetic signatures in cancer patients of non-European ancestry; identifies social adversity as a potential risk factor for higher rates of triple-negative breast cancer among Black women; shows a web-based system could help head-and-neck cancer survivors report their concerns; and finds adding immunotherapy can boost the effectiveness for hard-to-treat follicular lymphomas.
Feature
Dr. Andrew Vickers
The Truth About PSA Tests and Prostate Cancer Screening 

PSA testing is an important part of screening for prostate cancer, when it’s used the right way. Learn the truth dispelling seven myths about the PSA test.
Michael Rosensweig with dog
FDA Approves Revumenib, a Menin Inhibitor, for Aggressive Leukemia

Based on a clinical trial led by an MSK investigator, the FDA has approved revumenib (Revuforj®) for patients 1-year-old and older who have leukemia that has come back after treatment and whose cancer carries molecular changes called NPM1 mutations and KMT2A translocations.
Pattie Fuller smiles while wearing a pink plaid poncho
New Treatment for Metastatic (Stage 4) Melanoma: TIL Immunotherapy  

After immunotherapy and targeted therapy failed to bring a patient's melanoma under control, MSK doctors offered her a new treatment called tumor-infiltrating lymphocyte, or TIL, therapy.
Medical oncologist and prostate cancer specialist Dr. Wassim Abida
The Latest on Prostate Cancer Checkpoint Inhibitor Immunotherapy at MSK

Learn how genetic analysis of prostate cancer tumors is guiding treatment with checkpoint inhibitor immunotherapy.